Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans

Summary New drugs therapies have revolutionized the treatment of hepatitis C virus (HCV) infection. The objectives of this study were to evaluate uptake and utilization of boceprevir and telaprevir in the Department of Veterans Affairs (VA). We evaluated whether therapies conformed to response‐guide...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of viral hepatitis 2015-05, Vol.22 (5), p.489-495
Hauptverfasser: Gidwani, R., Barnett, P. G., Goldhaber-Fiebert, J. D., Asch, S. M., Lo, J., Dally, S. K., Owens, D. K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 495
container_issue 5
container_start_page 489
container_title Journal of viral hepatitis
container_volume 22
creator Gidwani, R.
Barnett, P. G.
Goldhaber-Fiebert, J. D.
Asch, S. M.
Lo, J.
Dally, S. K.
Owens, D. K.
description Summary New drugs therapies have revolutionized the treatment of hepatitis C virus (HCV) infection. The objectives of this study were to evaluate uptake and utilization of boceprevir and telaprevir in the Department of Veterans Affairs (VA). We evaluated whether therapies conformed to response‐guided protocols, whether they replaced standard interferon plus ribavirin treatment, and whether IL‐28B was used to guide treatment. We performed an administrative data‐based analysis of all patients receiving pharmacologic treatment for HCV in VA from October 2009 to July 2013. There were 12 737 new HCV prescriptions in VA during this time, with 5564 boceprevir or telaprevir prescriptions (44%) and 7173 prescriptions (56%) written for standard interferon plus ribavirin treatment. Prescriptions for the new treatments heavily favoured boceprevir vs telaprevir (83% vs 17%). Sixty‐two percent (62%) of boceprevir‐treated patients completed their minimum‐specified protocol, while 69.2% of telaprevir‐treated patients completed their minimum‐specified protocol. From October 2010 to July 2012, 4090 patients had an IL‐28B test; less than 16% of these tests guided subsequent HCV prescriptions. Uptake of boceprevir and telaprevir was rapid; the number of patients initiating treatment approximately doubled in the period after their introduction. While new prescriptions favor boceprevir or telaprevir over standard interferon plus ribavirin therapy, there appears to still be a strong role of interferon plus ribavirin in treating HCV patients. This work can inform our understanding of how other new effective HCV therapies will be used, their diffusion, and the timing of their diffusion in actual clinical practice.
doi_str_mv 10.1111/jvh.12344
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4390404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3646485401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4814-99f9fd793e526ec215906c7c0a44fc27bbd75d085d21d5fec00f13b9f699f32e3</originalsourceid><addsrcrecordid>eNp1kc1uEzEUha2qiJbCghdAlrpiMen138x4g4Si0oIqWEDaqhvL8diN06kntZ1AeHqcpo1ggTe25e-ce-SD0FsCI1LWyXw1GxHKON9Dh4TVoqKtZPubs6AVCOAH6FVKcwDCqCAv0QEVnDQtiEM0nyyyvrNYhw4vs-_9b539EPDgcOejNblfY22yD7cFyX7lo-7xve28eeQSdkPEM7sot-wTHmMfXFFtLHzAk9H3EV7ZbKMO6TV64XSf7Jun_QhNPp3-GJ9XF9_OPo8_XlSGt4RXUjrpukYyK2htDSVCQm0aA5pzZ2gznXaN6KAVHSWdKMMAHGFT6eqiZNSyI_Rh67tYTktSY0MuodUi-nsd12rQXv37EvxM3Q4rxZkEDrwYHD8ZxOFhaVNW82EZQ8msSN0AlJ-TrFDvt5SJQ0rRut0EAmpTiyq1qMdaCvvu70g78rmHApxsgZ--t-v_O6kvl-fPltVW4VO2v3YKHe9U3bBGqKuvZ4pcjaG9vmmVYH8API6n7Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1670078093</pqid></control><display><type>article</type><title>Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Gidwani, R. ; Barnett, P. G. ; Goldhaber-Fiebert, J. D. ; Asch, S. M. ; Lo, J. ; Dally, S. K. ; Owens, D. K.</creator><creatorcontrib>Gidwani, R. ; Barnett, P. G. ; Goldhaber-Fiebert, J. D. ; Asch, S. M. ; Lo, J. ; Dally, S. K. ; Owens, D. K.</creatorcontrib><description>Summary New drugs therapies have revolutionized the treatment of hepatitis C virus (HCV) infection. The objectives of this study were to evaluate uptake and utilization of boceprevir and telaprevir in the Department of Veterans Affairs (VA). We evaluated whether therapies conformed to response‐guided protocols, whether they replaced standard interferon plus ribavirin treatment, and whether IL‐28B was used to guide treatment. We performed an administrative data‐based analysis of all patients receiving pharmacologic treatment for HCV in VA from October 2009 to July 2013. There were 12 737 new HCV prescriptions in VA during this time, with 5564 boceprevir or telaprevir prescriptions (44%) and 7173 prescriptions (56%) written for standard interferon plus ribavirin treatment. Prescriptions for the new treatments heavily favoured boceprevir vs telaprevir (83% vs 17%). Sixty‐two percent (62%) of boceprevir‐treated patients completed their minimum‐specified protocol, while 69.2% of telaprevir‐treated patients completed their minimum‐specified protocol. From October 2010 to July 2012, 4090 patients had an IL‐28B test; less than 16% of these tests guided subsequent HCV prescriptions. Uptake of boceprevir and telaprevir was rapid; the number of patients initiating treatment approximately doubled in the period after their introduction. While new prescriptions favor boceprevir or telaprevir over standard interferon plus ribavirin therapy, there appears to still be a strong role of interferon plus ribavirin in treating HCV patients. This work can inform our understanding of how other new effective HCV therapies will be used, their diffusion, and the timing of their diffusion in actual clinical practice.</description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/jvh.12344</identifier><identifier>PMID: 25417805</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Antiviral Agents - therapeutic use ; boceprevir ; Drug Therapy, Combination - methods ; Drug Utilization ; Genotyping Techniques - statistics &amp; numerical data ; Hepacivirus ; Hepatitis C, Chronic - drug therapy ; Humans ; IL-28B ; Interferon ; Interferon-alpha - therapeutic use ; Interferons ; Interleukins - genetics ; Oligopeptides - therapeutic use ; Proline - analogs &amp; derivatives ; Proline - therapeutic use ; Retrospective Studies ; ribavirin ; Ribavirin - therapeutic use ; telaprevir ; United States ; Veterans</subject><ispartof>Journal of viral hepatitis, 2015-05, Vol.22 (5), p.489-495</ispartof><rights>2014 John Wiley &amp; Sons Ltd</rights><rights>2014 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2015 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4814-99f9fd793e526ec215906c7c0a44fc27bbd75d085d21d5fec00f13b9f699f32e3</citedby><cites>FETCH-LOGICAL-c4814-99f9fd793e526ec215906c7c0a44fc27bbd75d085d21d5fec00f13b9f699f32e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvh.12344$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjvh.12344$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25417805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gidwani, R.</creatorcontrib><creatorcontrib>Barnett, P. G.</creatorcontrib><creatorcontrib>Goldhaber-Fiebert, J. D.</creatorcontrib><creatorcontrib>Asch, S. M.</creatorcontrib><creatorcontrib>Lo, J.</creatorcontrib><creatorcontrib>Dally, S. K.</creatorcontrib><creatorcontrib>Owens, D. K.</creatorcontrib><title>Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description>Summary New drugs therapies have revolutionized the treatment of hepatitis C virus (HCV) infection. The objectives of this study were to evaluate uptake and utilization of boceprevir and telaprevir in the Department of Veterans Affairs (VA). We evaluated whether therapies conformed to response‐guided protocols, whether they replaced standard interferon plus ribavirin treatment, and whether IL‐28B was used to guide treatment. We performed an administrative data‐based analysis of all patients receiving pharmacologic treatment for HCV in VA from October 2009 to July 2013. There were 12 737 new HCV prescriptions in VA during this time, with 5564 boceprevir or telaprevir prescriptions (44%) and 7173 prescriptions (56%) written for standard interferon plus ribavirin treatment. Prescriptions for the new treatments heavily favoured boceprevir vs telaprevir (83% vs 17%). Sixty‐two percent (62%) of boceprevir‐treated patients completed their minimum‐specified protocol, while 69.2% of telaprevir‐treated patients completed their minimum‐specified protocol. From October 2010 to July 2012, 4090 patients had an IL‐28B test; less than 16% of these tests guided subsequent HCV prescriptions. Uptake of boceprevir and telaprevir was rapid; the number of patients initiating treatment approximately doubled in the period after their introduction. While new prescriptions favor boceprevir or telaprevir over standard interferon plus ribavirin therapy, there appears to still be a strong role of interferon plus ribavirin in treating HCV patients. This work can inform our understanding of how other new effective HCV therapies will be used, their diffusion, and the timing of their diffusion in actual clinical practice.</description><subject>Antiviral Agents - therapeutic use</subject><subject>boceprevir</subject><subject>Drug Therapy, Combination - methods</subject><subject>Drug Utilization</subject><subject>Genotyping Techniques - statistics &amp; numerical data</subject><subject>Hepacivirus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>IL-28B</subject><subject>Interferon</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferons</subject><subject>Interleukins - genetics</subject><subject>Oligopeptides - therapeutic use</subject><subject>Proline - analogs &amp; derivatives</subject><subject>Proline - therapeutic use</subject><subject>Retrospective Studies</subject><subject>ribavirin</subject><subject>Ribavirin - therapeutic use</subject><subject>telaprevir</subject><subject>United States</subject><subject>Veterans</subject><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1uEzEUha2qiJbCghdAlrpiMen138x4g4Si0oIqWEDaqhvL8diN06kntZ1AeHqcpo1ggTe25e-ce-SD0FsCI1LWyXw1GxHKON9Dh4TVoqKtZPubs6AVCOAH6FVKcwDCqCAv0QEVnDQtiEM0nyyyvrNYhw4vs-_9b539EPDgcOejNblfY22yD7cFyX7lo-7xve28eeQSdkPEM7sot-wTHmMfXFFtLHzAk9H3EV7ZbKMO6TV64XSf7Jun_QhNPp3-GJ9XF9_OPo8_XlSGt4RXUjrpukYyK2htDSVCQm0aA5pzZ2gznXaN6KAVHSWdKMMAHGFT6eqiZNSyI_Rh67tYTktSY0MuodUi-nsd12rQXv37EvxM3Q4rxZkEDrwYHD8ZxOFhaVNW82EZQ8msSN0AlJ-TrFDvt5SJQ0rRut0EAmpTiyq1qMdaCvvu70g78rmHApxsgZ--t-v_O6kvl-fPltVW4VO2v3YKHe9U3bBGqKuvZ4pcjaG9vmmVYH8API6n7Q</recordid><startdate>201505</startdate><enddate>201505</enddate><creator>Gidwani, R.</creator><creator>Barnett, P. G.</creator><creator>Goldhaber-Fiebert, J. D.</creator><creator>Asch, S. M.</creator><creator>Lo, J.</creator><creator>Dally, S. K.</creator><creator>Owens, D. K.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>5PM</scope></search><sort><creationdate>201505</creationdate><title>Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans</title><author>Gidwani, R. ; Barnett, P. G. ; Goldhaber-Fiebert, J. D. ; Asch, S. M. ; Lo, J. ; Dally, S. K. ; Owens, D. K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4814-99f9fd793e526ec215906c7c0a44fc27bbd75d085d21d5fec00f13b9f699f32e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>boceprevir</topic><topic>Drug Therapy, Combination - methods</topic><topic>Drug Utilization</topic><topic>Genotyping Techniques - statistics &amp; numerical data</topic><topic>Hepacivirus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>IL-28B</topic><topic>Interferon</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferons</topic><topic>Interleukins - genetics</topic><topic>Oligopeptides - therapeutic use</topic><topic>Proline - analogs &amp; derivatives</topic><topic>Proline - therapeutic use</topic><topic>Retrospective Studies</topic><topic>ribavirin</topic><topic>Ribavirin - therapeutic use</topic><topic>telaprevir</topic><topic>United States</topic><topic>Veterans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gidwani, R.</creatorcontrib><creatorcontrib>Barnett, P. G.</creatorcontrib><creatorcontrib>Goldhaber-Fiebert, J. D.</creatorcontrib><creatorcontrib>Asch, S. M.</creatorcontrib><creatorcontrib>Lo, J.</creatorcontrib><creatorcontrib>Dally, S. K.</creatorcontrib><creatorcontrib>Owens, D. K.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gidwani, R.</au><au>Barnett, P. G.</au><au>Goldhaber-Fiebert, J. D.</au><au>Asch, S. M.</au><au>Lo, J.</au><au>Dally, S. K.</au><au>Owens, D. K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2015-05</date><risdate>2015</risdate><volume>22</volume><issue>5</issue><spage>489</spage><epage>495</epage><pages>489-495</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract>Summary New drugs therapies have revolutionized the treatment of hepatitis C virus (HCV) infection. The objectives of this study were to evaluate uptake and utilization of boceprevir and telaprevir in the Department of Veterans Affairs (VA). We evaluated whether therapies conformed to response‐guided protocols, whether they replaced standard interferon plus ribavirin treatment, and whether IL‐28B was used to guide treatment. We performed an administrative data‐based analysis of all patients receiving pharmacologic treatment for HCV in VA from October 2009 to July 2013. There were 12 737 new HCV prescriptions in VA during this time, with 5564 boceprevir or telaprevir prescriptions (44%) and 7173 prescriptions (56%) written for standard interferon plus ribavirin treatment. Prescriptions for the new treatments heavily favoured boceprevir vs telaprevir (83% vs 17%). Sixty‐two percent (62%) of boceprevir‐treated patients completed their minimum‐specified protocol, while 69.2% of telaprevir‐treated patients completed their minimum‐specified protocol. From October 2010 to July 2012, 4090 patients had an IL‐28B test; less than 16% of these tests guided subsequent HCV prescriptions. Uptake of boceprevir and telaprevir was rapid; the number of patients initiating treatment approximately doubled in the period after their introduction. While new prescriptions favor boceprevir or telaprevir over standard interferon plus ribavirin therapy, there appears to still be a strong role of interferon plus ribavirin in treating HCV patients. This work can inform our understanding of how other new effective HCV therapies will be used, their diffusion, and the timing of their diffusion in actual clinical practice.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25417805</pmid><doi>10.1111/jvh.12344</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1352-0504
ispartof Journal of viral hepatitis, 2015-05, Vol.22 (5), p.489-495
issn 1352-0504
1365-2893
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4390404
source MEDLINE; Wiley Online Library All Journals
subjects Antiviral Agents - therapeutic use
boceprevir
Drug Therapy, Combination - methods
Drug Utilization
Genotyping Techniques - statistics & numerical data
Hepacivirus
Hepatitis C, Chronic - drug therapy
Humans
IL-28B
Interferon
Interferon-alpha - therapeutic use
Interferons
Interleukins - genetics
Oligopeptides - therapeutic use
Proline - analogs & derivatives
Proline - therapeutic use
Retrospective Studies
ribavirin
Ribavirin - therapeutic use
telaprevir
United States
Veterans
title Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T02%3A09%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Uptake%20and%20utilization%20of%20directly%20acting%20antiviral%20medications%20for%20hepatitis%20C%20infection%20in%20U.S.%20veterans&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Gidwani,%20R.&rft.date=2015-05&rft.volume=22&rft.issue=5&rft.spage=489&rft.epage=495&rft.pages=489-495&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/jvh.12344&rft_dat=%3Cproquest_pubme%3E3646485401%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1670078093&rft_id=info:pmid/25417805&rfr_iscdi=true